A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma
Cecilia Carpio,Loic Ysebaert,Raul Cordoba,Armando Santoro,José Antonio López-Martín,Juan M. Sancho,Carlos Panizo,Mecide Gharibo,Drew W. Rasco,Anne-Marie Stoppa,Sylvia Damian,Xin Wei,Patrick Hagner,Kristen Hege,Soraya Carrancio,Anita Gandhi,Michael Pourdehnad,Vincent Ribrag +17 more
TL;DR: A second cohort of DLBCL subjects was enrolled to evaluate the tolerability and clinical activity of intermittent schedules of CC-122 and 22 subjects with relapsed/refractoryDLBCL were enrolled in the 2nd cohort; all were evaluable for safety, 16 were efficacy evaluable (EE) as of the cutoff date.
Journal ArticleDOI
Rapid and Wide Immunereconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT.
Chiara Bonini,Fabio Ciceri,Maria Teresa Lupo Stanghellini,Attilio Bondanza,Zulma Magnani,Serena K. Perna,Massimo Bernardi,Jacopo Peccatori,Paolo Servida,Fulvio Crippa,Shin Kaneko,Veronica Valtolina,Monica Salomoni,Lucia Turchetto,Salvatore Toma,Catia Traversari,Paolo Bruzzi,Luca Castagna,Armando Santoro,Jane F. Apperley,Shimon Slavin,Scialini Colombi,Corrado Gallo Stampino,Marco Bregni,Claudio Bordignon +24 more
TL;DR: Results indicate that TK-DLI abolish late mortality after CD34+ haplo-SCT in adults with high risk malignancies, lacking a conventional donor.
Journal ArticleDOI
Randomized phase II study of neoadjuvant chemotherapy in soft tissue sarcomas in adults. Protocol 62874
E. Gortzak,Jacques Rouëssé,J. Verwey,A.N. van Geel,J. Buesa,Armando Santoro,T. Tursz,M. van Glabbeke,Kirkpatricka,Henning T. Mouridsen +9 more
Journal ArticleDOI
Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.
Elisabetta Todisco,Barbara Sarina,Luca Castagna,Rita Mazza,Daoud Rahal,Andrea Nozza,Armando Santoro +6 more
TL;DR: A case of extensive chronic GVHD (cGVHD) and post-ASCT extramedullary myeloma progression, which were both responsive to bortezomib.
Journal ArticleDOI
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).
Silvia Bozzarelli,Lorenza Rimassa,Laura Giordano,Simona Sala,Maria Chiara Tronconi,Tiziana Pressiani,Valeria Smiroldo,Maria Giuseppina Prete,Paola Spaggiari,Nicola Personeni,Armando Santoro +10 more
TL;DR: The Phase II pancreatic adenocarcinoma cohort study did not meet its primary end point and further investigation of regorafenib monotherapy in this setting is not recommended.